Pair page
DSIP with Selank
Mechanism-tag overlap and published literature for DSIP and Selank, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
neuroregulatory-nonapeptide-historical-sleep-factor
anxiolytic-nootropictuftsin-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying DSIP and Selank have published these mechanism-level observations. Not a co-administration recommendation.
Russian anxiolytic tuftsin-derived intranasal peptide. Occasionally paired with DSIP in sleep/anxiety community protocols. Both small BBB-penetrant peptides.
Quick facts
DSIP
Selank
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 1992 | DSIP | Kaeser HE, Mouret J, Helmert DS. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Eur Neurol. 1992;32(Suppl 1):22-27. PMID: 1299794. (Double-blind negative/marginal result for chronic insomnia.) PMID 1299794 | human trial |
| 1984 | DSIP | Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. 1984;23(5):372-385. | human pilot |
| 1995 | DSIP | Vgontzas AN, Friedman TC, Chrousos GP, Bixler EO, Vela-Bueno A, Kales A. Delta sleep-inducing peptide in normal humans and in patients with sleep apnea and narcolepsy. J Sleep Res. 1995;4(S1):224-229. (Observational peptide-level study.) | human study |
| 1984 | DSIP | Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984;23(5):364-371. PMID: 6548969. (The 107-patient alcohol/opiate withdrawal study.) PMID 6548969 | human study |
| 1984 | DSIP | Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Psychoneuroendocrinology. 1984;9(1):83-89. PMID: 6328354. PMID 6328354 | human study |
| 1992 | DSIP | Salieva RM, Ivanov DS, Lastochkina NA. Delta sleep-inducing peptide as a factor increasing the content of substance P in the hypothalamus and the resistance of rats to emotional stress. Neurosci Behav Physiol. 1992;22(4):275-279. (Stress-resistance rodent paper.) | preclinical, in vivo |
| 1985 | DSIP | Graf MV, Kastin AJ, Schoenenberger GA. Delta sleep-inducing peptide in spontaneously hypertensive rats. Peptides. 1985;6(6):1043-1046. | preclinical, in vivo |
| 1982 | DSIP | Riou F, Cespuglio R, Jouvet M. Endogenous peptides and sleep in the rat. III. The hypnogenic properties of vasoactive intestinal peptide. Neuropeptides. 1982;2(5):265-277. (Context for sleep-peptide field.) | preclinical, in vivo |
| — | DSIP | Cadelis G, Bove P, Mondon K, Albaret JM. Transport and metabolism of delta sleep-inducing peptide in cultured human intestinal epithelial cell monolayers. (Caco-2 oral-absorption paper.) | preclinical, in vitro |
| 1985 | DSIP | Banks WA, Kastin AJ. Passage of delta sleep-inducing peptide (DSIP) across the blood-cerebrospinal fluid barrier. Peptides. 1985;6(1):71-75. (BBB-penetration characterization.) | mechanism / discovery |
| 1977 | DSIP | Monnier M, Dudás B, Prochiantz A. Sleep-inducing factor: a neuropeptide? Nature. 1977;268(5616):152-153. (Foundational isolation paper.) | mechanism / discovery |
| 2006 | DSIP | Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a sleep-inducing agent or a universal homeostasis regulator? Zh Evol Biokhim Fiziol. 2006;42(1):3-10. (Russian-language review, English abstract — recent perspective on DSIP's mechanism and role.) | review |
| 2008 | Selank | Zozulia AA, Neznamov GG, Syunyakov TS, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096. (Russian Phase… PMID 18454096 | human trial, Phase 3 |
| 2015 | Selank | Medvedev VE, Teresh'chenko OE, Israelyan AY, et al. [Optimization of therapy with traditional anxiolytic drugs in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(4):33-40. | human study |
| 2008 | Selank | Uchakina ON, Uchakin PN, Miasoedov NF, et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. | human study |
| 2019 | Selank | Inozemtseva LS, Kudryavtseva NN, Bobkova NV, Dolotov OV, Gerasimova OA, Levitskaya NG, Kamensky AA, Andreeva LA, Myasoedov NF, Grivennikov IA. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus… PMID 31625062 | preclinical, in vivo |
| 2017 | Selank | Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Biomed Res Int. 2017;2017:2875904. PMC5322660. | preclinical, in vivo |
| 2008 | Selank | Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. PMID: 18841778. PMID 18841778 | preclinical, in vivo |
| 2007 | Selank | Semenova TP, Medvinskaia NI, Nesterova IV, Kozlovskaia MM. [Experimental analysis of the effect of Selank on the emotional and cognitive behavior of mice]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2007;57(6):738-743. | preclinical, in vivo |
| 1998 | Selank | Seredenin SB, Kozlovskaia MM, Blednov IuA, Kozlovskii II. [Anxiolytic properties of Selank in BALB/c mice with differences in dopamine system reactivity]. Biull Eksp Biol Med. 1998;126(4):402-406. PMID: 9868709. PMID 9868709 | preclinical, in vivo |
| 2009 | Selank | Russian Federation State Register of Medicines. Selank — 0.15% intranasal solution. Approved 2009. | regulatory / registry |
| 2017 | Selank | Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, Limborska S, Myasoedov N, Pavlova G, Slominsky P, Shadrina M. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89. PMID… PMID 28316569 | research article |
| 2016 | Selank | Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26903861. PMC4757669. PMID 26903861 | research article |
| 2003 | Selank | Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003;33(7):639-643. PMID: 14552536. PMID 14552536 | research article |
Related pair pages
More research context
Frequently asked
Have DSIP and Selank been studied together?
Researchers have published mechanistic-level co-administration discussion of DSIP and Selank. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do DSIP and Selank share?
DSIP and Selank do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of DSIP and Selank?
DSIP: Not approved. Selank: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on DSIP and Selank?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the DSIP profile and the Selank profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026